Zealand Pharma A/S (NASDAQ:ZLDPF) Upgraded to “Hold” at Zacks Investment Research

Zacks Investment Research upgraded shares of Zealand Pharma A/S (NASDAQ:ZLDPF) from a sell rating to a hold rating in a research report sent to investors on Tuesday, July 25th.

According to Zacks, “Zealand Pharma A/S is a biotechnology company. It focused on the discovery, design and development of peptide-based medicines. The company’s pipeline includes ZP4207, single-dose rescue treatment for acute, severe hypoglycemia; ZP1848 for short bowel syndrome and ZP4207, multiple-dose version intended for use in a dual-hormone artificial pancreas system for better hypoglycemia control and diabetes management and other earlier-stage clinical and preclinical peptide therapeutics are in clinical stage. Zealand Pharma A/S is based in Copenhagen, Denmark. “

Zealand Pharma A/S (NASDAQ ZLDPF) remained flat at $18.95 during trading on Tuesday. Zealand Pharma A/S has a 1-year low of $14.95 and a 1-year high of $19.51. The firm has a 50 day moving average of $18.19 and a 200-day moving average of $17.27. The stock’s market capitalization is $484.72 million.

COPYRIGHT VIOLATION WARNING: “Zealand Pharma A/S (NASDAQ:ZLDPF) Upgraded to “Hold” at Zacks Investment Research” was first published by Stock Observer and is the sole property of of Stock Observer. If you are viewing this report on another website, it was stolen and reposted in violation of U.S. and international copyright law. The legal version of this report can be accessed at https://www.thestockobserver.com/2017/08/12/zealand-pharma-as-nasdaqzldpf-upgraded-at-zacks-investment-research-updated-updated.html.

Get a free copy of the Zacks research report on Zealand Pharma A/S (ZLDPF)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Zealand Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zealand Pharma A/S and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply